Weekend Long Read: A Chinese Startup’s Moonshot Cancer Cure

1. Chen Li's Likang Life Sciences is pioneering personalized cancer vaccines using mRNA and AI, aiming to shift cancer treatment from broad drugs to molecule-specific therapies tailored to each patient's tumor genetic signature, potentially improving response rates dramatically [para. 1][para. 2].

2. Likang, a startup founded less than a decade ago, has secured clinical trial authorization in China and U.S. FDA IND clearance in 2025, positioning it ahead in the competitive field shared by giants like Moderna and BioNTech [para. 3][para. 26].

3. Chen, 38, entered biotech due to his mother's 2016 late-stage ovarian cancer diagnosis; as a PhD student in tumor immunology, he couldn't find collaborators, so he developed a personalized therapy himself, achieving her remission [para. 4][para. 5][para. 6][para. 7][para. 8][para. 9][para. 10][para. 11][para. 12].

4. In 2017, Chen founded Likang to scale this approach, abandoning academia after proving the concept on his mother [para. 13].

5. Likang's core idea: cancers are unique due to patient-specific mutations, unlike generalized treatments like PD-1 inhibitors with limited response rates; they sequence tumors/blood, use AI to identify immune-triggering mutations (dozens per patient), encode ~30 into mRNA vaccines delivered via dendritic cells or nanoparticles to train the immune system broadly, contrasting CAR-T's single-target focus [para. 14][para. 15][para. 16][para. 17][para. 18][para. 19].

6. Early data: 2018 first-in-human study of 24 intermediate-stage liver cancer patients showed 100% five-year survival; advanced melanoma trials reported 29-week median progression-free survival, over double the 13 weeks for PD-1 monotherapy in comparable data [para. 21][para. 22][para. 23].

7. Preliminary results enabled progress: China's NMPA approval in 2023 for first AI-driven personalized mRNA tumor vaccine trials; FDA IND in 2025 for international trials [para. 24][para. 25].

8. Chen likens the race to reaching the moon's Holy Grail, emphasizing engineering challenges in target ID (navigation), delivery (propulsion), and patient selection [para. 27][para. 28].

9. In Hainan pilot zone, treatment available since 2025 at 150,000 yuan (~$22,000) per injection, ~1 million yuan for seven-injection course; scaling via expanded manufacturing, plus developing standardized therapies [para. 30][para. 31].

10. Likang reflects China's biotech surge: regulatory reforms, funding access, returning talent; China now sources many global licensing deals, though U.S./Europe expansion needs partnerships [para. 32][para. 33][para. 34][para. 35].

11. Chen is cautiously optimistic: cancer as 1,000+ diseases means uneven progress, but genomics/AI/immunology convergence offers hope for extended lifespans; focus on trials, data, approvals [para. 36][para. 37][para. 38][para. 39][para. 40][para. 41].

(Word count: 498)